Navigation Links
Spirit II explores long-term performance of XIENCE V stent
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-coated XIENCE V stent may continue to hold a clinical edge over its paclitaxel-coated competitor.

The two-year findings of the SPIRIT II study are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Patrick W. Serruys, MD, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands, led the SPIRIT II study. He and his colleagues recruited 300 patients from 28 medical centers in Europe, New Zealand and India who needed stenting of up to two new coronary lesions. Patients were randomly assigned to treatment with the XIENCE V everolimus-eluting stent or the Taxus paclitaxel-eluting stent.

The study primarily set out to document any differences in the amount of arterial tissue that grew into the stents at six months (in-stent late loss). As previously reported, the results were significantly better for the XIENCE V stent when compared to the Taxus stent. At one-year follow-up, the combined rates of major adverse cardiac events (MACE), consisting of cardiac death, heart attack and repeat procedure to treat the target lesion, trended better in the XIENCE V group.

New data from a late-stage evaluation report demonstrates that the XIENCE V stent continues to show a trend toward improved clinical outcomes compared to the Taxus stent at two years, however, the trial was not statistically powered to show differences in c
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12
2. Most Psychiatrists Open to Discussing Spiritual Concerns
3. Health Care Bill Omits Access to Spiritual Care
4. New Yorkers Deserve Access to Spiritually Based Healing
5. Spirituality Helps Older Black Women Beat Hypertension
6. Living Your Best Life: Adjusting Mind, Body and Spirit
7. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
8. Wine, women and... spirits, beer and breast cancer risk
9. USA TODAY Concludes Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
10. Spiritual Healer/Psychic-Medium Reaches International Status!
11. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...ubstantially higher rates of mental health problem...s from a systematic review and meta-analysis publi...or studies over the past four decades containing d...ess people, Seena Fazel and colleagues of the Univ...,684 homeless individuals based in the US, UK, mai...
(Date:12/2/2008)...mposium today hosted by Johns,Hopkins University...s presented,the latest research in brain plastici... into technology to improve lives. Henry Mahncke, ...e that cognitive intervention developed by,Posit ...s ability to,reorganize itself throughout life. ...
(Date:12/2/2008)... assault are unsettling; the Department of Justice...e victim of attempted or actual sexual assault dur...rs from two universities, including the University...are unaware of drug-facilitated sexual assault and...including leaving drinks unattended. , "These f...
(Date:12/2/2008)...rprise software and online services veteran is exp...ers of Yugma,s instant web conferencing solutions ... December 2, 2008 -- Yugma , the leading web conf...aborate instantly using the Internet, announced th... Officer. , , ,Vas has more than 20 years of exper...
Breaking Medicine News(10 mins):Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3
... dengue cases in the national capital civic author...k the menace//, including prosecuting people who c...v, deputy municipal health officer of Delhi said, ...ted of which six proved to be fatal. We have recei...
...ealthcare treatment meted to those suffering menta...udy has found.// An investigation of 8 million hea...s opened a can of worms. The study spanning 18 m... a propensity suffer other illness alongside, as c...
...re is a “crisis” over lack of donors at sperm bank...linics being totally out of stock//, women and cou...problem. In 1990s, the highest number of donors w...decreasing. To make it worse, last year a new law ...
... reduce the bio-terrorism threat of the Venezuelan...hers at the University of Texas Medical Branch at ...al step in the development of effective drug thera...litis (VEE) virus, which is a potential bio-terror...
Other Medicine News:Health News:Shortage of donors at sperm bank clinics 2Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2
(Date:12/1/2008)...PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc...ncet , one of the world,s leading medical journals...n regulator, experimental compound tasimelteon (VE... entitled "Melatonin agonist tasimelteon (VEC-162)...o randomised controlled multicentre trials." Resul...
(Date:12/1/2008)...hatasia Treated With ENB-0040 at Children,s Hospit...MONTREAL, Dec. 1 Enobia Pharma, an...loping novel therapeutics for serious bone disorde...in its clinical program for hypophosphatasia was d...herapy (ERT) with ENB-0040 for the treatment of th...
(Date:12/1/2008)...December 1 Following a,...t to procure an MVA-based,third generation small...,Canada, on behalf of the Canadian Department of N...an Nordic for the delivery of IMVAMUNE(R). , ...R) as part of the,country,s bio-preparedness prog...
(Date:11/30/2008).... 1 Older adults who ex...w and a greater number of small blood vessels in t... the annual meeting of the Radiological Society of...ucted at the University of North Carolina ( UNC)...ns of older adults who exercise to brain scans of ...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Thyroid Hormone Could One Day Treat Osteoporosis 13954 1Thyroid Hormone Could One Day Treat Osteoporosis 13954 2Thyroid Hormone Could One Day Treat Osteoporosis 13954 3Alarming growth in expected CO2 emissions in China finds UC analysis 2451 1Alarming growth in expected CO2 emissions in China finds UC analysis 2451 2Alarming growth in expected CO2 emissions in China finds UC analysis 2451 3GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 1GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 2GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 3Injection of human umbilical cord blood helps the aging brain 13948 1Injection of human umbilical cord blood helps the aging brain 13948 2
...ay 29, 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) ...007) study of aztreonam lysine for inhalation for,...who have,pulmonary Pseudomonas aeruginosa (P. aeru...e at Day 28 from baseline in respiratory,symptoms,...Revised,(CFQ-R), a patient-reported outcome (PRO) ...
...for Organ Transplantation, HORSHOLM, Denmark, May ...a announces positive Phase I clinical results for,... Heads into US,Phase II clinical trials for organ ...:LCP) announces positive results,from its Phase I ..., once-daily tacrolimus tablet. , A series of Phas...
Other Medicine Technology:Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
VERSASTEP™ Reposable Short Single-Use For use with VERSASTEP™ Short Reusable Cannula, Dilator.
VersaStep™ Reposable Sterilization Trays.
VERSASTEP™ Plus Long Instrument for applications in laparoscopic procedures., ,The VERSASTEP™ Plus Long Instrument with 150mm Working Length is a unique endoscopic entry device that has
...ade; Blunt Tip Trocar consists of a blunt obturato... , ,The valve body assembly contains an internal ... instruments are inserted or withdrawn. The Autosu...verters to allow insertion of instruments of diffe...
Medicine Products: